C31G is a potent broad spectrum antimicrobial agent, effective against gram positive and gram negative bacteria, yeast and fungi.C31G, vaginal gel is developed by Biosyn Inc. and has commenced enrollment in a phase III pivotal clinical trial for the reduction of sexual transmission of human immunodeficiency virus (HIV).
Investigated for use/treatment in contraception, HIV infection, and prevention of stdis.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.